SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention as its Phase 3 REGAL AML trial approaches the 80th death event that will trigger final efficacy analysis, with traders focused on the prospect of a major binary catalyst. Bulls point to the prolonged survival timeline and supportive comments from pharmaceutical-industry professionals, while bears debate trial design, dosing changes, censoring, and whether the delay signals control-arm strength or statistical risk.

Zoracles

A sharp rally in low-cap ZORA, accompanied by higher volume, has prompted traders to discuss a possible technical breakout and speculative short squeeze tied to sizable futures positioning. The community is divided between bullish accumulation and creator/attention-market utility narratives versus warnings that the move may be a temporary pump-and-dump or reflect broader Bitcoin-driven volatility.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

Reported ARK Invest accumulation of SpaceX shares, including a sizable allocation in ARKK, has become the main focus, reinforcing the ETFs concentrated exposure to high-growth space and technology themes. Traders are divided between viewing the purchases as conviction in long-term innovation and criticizing the timing, valuation risk, and ARKKs prolonged underperformance.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Modernas reported positive Phase 3 cancer-vaccine result has made ARCT a sympathy trade, drawing attention to Arcturuss self-amplifying mRNA platform and related oncology potential. Bulls are also highlighting upcoming CF and OTC-deficiency milestones and short interest, while skeptics point to mixed ARCT-032 data and caution that the rally may be technically overbought.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Speculation that SK Hynix may outsource advanced HBM base-die production to Intel Foundry has fueled interest, alongside broader expectations for additional 14A and AI-related foundry customers. Traders are largely bullish on the potential customer wins, though some caution that the SK Hynix discussions remain unconfirmed and could become a buy the rumor, sell the news event amid concerns about Intels foundry profitability.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforces strong quarterly results, raised outlook, and expanded Anthropic partnership through Claudeforce have fueled a sharp rally, reinforcing the view that AI can augmentand monetizeenterprise software rather than replace it. Traders are broadly bullish and citing short covering and a broader software rotation, though some warn the move is overextended and expect profit-taking or a pullback.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Progress on the proposed European Lithium merger including an amended floating share-exchange ratio, potential cancellation of existing CRML shares, court proceedings, and expected cash inflowhas driven the dominant discussion. Bullish traders view the deal as reducing dilution and strengthening CRMLs rare-earths and lithium platform, while skeptics remain focused on execution delays, future dilution, and the companys pre-revenue status, with short-squeeze speculation amplifying volatility.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Strong second-quarter execution, profitability, and an improved outlook are fueling renewed interest, alongside speculation that BioCryst could acquire additional rare-disease assets or become a takeover target. Traders remain divided, with bulls citing Orladeyos cash generation and future navenibart potential, while skeptics focus on stagnant price action, dilution, competition from PHVS, and uncertainty around the companys external-pipeline strategy.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeriss September 9 XP-8121 program webinar, covering the Phase 3 design, development plan, and commercial opportunity for its once-weekly injectable levothyroxine, is the dominant catalyst. Traders view the event as a potential valuation inflection point alongside Recorlev growth, while some caution that buyout or partnership speculation is unsubstantiated and the presentation could disappoint or trigger a sell-the-news reaction.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

High-level discussions between QuantumScape and Indian officials about next-generation batteries and potential manufacturing or EV-ecosystem collaboration are fueling speculation about a new commercial opportunity in India. Traders remain divided, with bulls viewing the countrys large electric two-wheeler market as a catalyst while skeptics emphasize that concrete production, licensing, and customer milestones remain unconfirmed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The More Life Co. Corp. is a biotechnology company, which engages in the provision of solutions to optimize human, animal, and plant health. Its patented technologies includes Quicksome™ and Quicksol™. The Quicksome™ patented technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into product formats that, if successfully commercialized, could enhance the efficacy of molecule delivery across a variety of nutraceutical product applications. The Quicksol™ patented is a solubilization technology, which has been developed to provide solubilized drug delivery options. The company was founded on March 8, 2005 and is headquartered in Vaughan, Canada.

More Life Company Corp (The)

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a positive week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.0511
Prev Close	$0.0471
Open	$0.05
Dividend Yield	N/A
50-Day Moving Average	$0.054
Beta	-0.42
Avg. Volume	23,458.32
PE Ratio	-8.96

52-Week High	$0.0887
52-Week Low	$0.0074
Market Capitalization	$23.35M
EPS (Annual)	-$0.0057
Price to Book	-176.21
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info